Breaking News Instant updates and real-time market news.

SSTI

ShotSpotter

$24.03 /

+0.7 (+3.00%)

09:03
11/26/19
11/26
09:03
11/26/19
09:03

ShotSpotter announces three-year $4.27M contract with Puerto Rico

ShotSpotter announced that it has officially signed a three-year, $4.27M contract with the Puerto Rico Public Housing Authority to deploy its gunshot detection technology in the largest metropolitan area on the island, including portions of the capital San Juan and neighboring municipalities Bayamon and Trujillo Alto. The company expects to complete the deployment and go live in all of the coverage areas by the end of the first calendar quarter of 2020.

SSTI ShotSpotter
$24.03 /

+0.7 (+3.00%)

11/13/19 NATL
ShotSpotter upgraded to Buy from Neutral at National Securities
11/13/19 NORL
ShotSpotter price target lowered to $25 from $40 at Northland
11/13/19 LSCM
ShotSpotter price target lowered to $23 from $40 at Lake Street
11/14/19 ROTH
ShotSpotter price target lowered to $33 from $64 at Roth Capital

TODAY'S FREE FLY STORIES

Initiation
Matinas BioPharma initiated with an Overweight at Piper Sandler » 21:11
01/26/20
01/26
21:11
01/26/20
21:11
MTNB

Matinas BioPharma

$1.48 /

-0.01 (-0.67%)

, AMRN

Amarin

$20.22 /

-0.53 (-2.55%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff initiated coverage of Matinas BioPharma (MTNB) with an Overweight rating and $3 price target. The stock closed Friday down 4c to $1.47. Matinas is developing MAT9001, a prescription omega-3 fish oil for severe hypertriglyceridemia, Tenthoff tells investors in a research note. Based on positive REDUCE-IT outcomes data, the FDA recently expanded the label of Amarin's (AMRN) Vascepa to include cardiovascular disease patients with high triglycerides of greater than 150 mg/dL, the analyst points out. Cardiovascular disease. He notes that in 2015, Matinas reported data from a Phase I study showing MAT9001 to have superior triglyceride lowering of 33% versus 11% with Vascepa. Matinas, which is now conducting the Phase II ENHANCE-IT study of MAT9001 versus Vascepa with data in Q4 of this year, could begin a single Phase III severe hypertriglyceridemia trial in 2021 with potential approval in 2023, contends Tenthoff. The analyst sees growing importance of omega-3 fish oils.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Denali Therapeutics upgraded to Buy from Neutral at Goldman Sachs » 19:59
01/26/20
01/26
19:59
01/26/20
19:59
DNLI

Denali Therapeutics

$24.68 /

-0.26 (-1.04%)

, SNY

Sanofi

$48.73 /

-0.88 (-1.77%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter upgraded Denali Therapeutics (DNLI) to Buy from Neutral with a price target of $37, up from $20. The analyst believes the Denali is evolving into a triple platform story with a small molecule portfolio targeting mutated genetic targets/pathways; a leverageable multi-modality blood brain barrier Transport Vehicle platform; and a potential next-generation viral vector gene therapy vertical. With positive updates from Ph1b DNL201 and Ph1 DNL151, Richter has increased confidence in the program and await initial Sanofi (SNY)-partnered Ph1b DNL747 biomarker data in Alzheimer disease and ALS in mid-2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: Top five weekend stock stories » 19:50
01/26/20
01/26
19:50
01/26/20
19:50
SNE

Sony

$71.89 /

-0.7 (-0.96%)

, ATVI

Activision Blizzard

$59.36 /

-0.77 (-1.28%)

, MSFT

Microsoft

$165.03 /

-1.69 (-1.01%)

, AMZN

Amazon.com

$1,862.09 /

-22.76 (-1.21%)

, SBUX

Starbucks

$92.03 /

-1.72 (-1.83%)

, ABBV

AbbVie

$83.53 /

-1.73 (-2.03%)

, GOOGL

Alphabet Class A

$1,465.80 /

-19.06 (-1.28%)

, GOOG

Alphabet

$1,466.47 /

-19.67 (-1.32%)

, HPQ

HP Inc.

$21.99 /

-0.115 (-0.52%)

, OMC

Omnicom

$77.71 /

-1.05 (-1.33%)

, IPG

Interpublic Group

$23.41 /

-0.13 (-0.55%)

, PUBGY

Publicis

$0.00 /

+ (+0.00%)

, WPP

WPP

$65.07 /

-0.81 (-1.23%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. U.S. state attorneys general will meet Justice Department attorneys next week to share information on their investigations into Alphabet's (GOOG) Google, Reuters' Nandita Bose wrote, citing two sources familiar with the matter. The probes revolve around monopolistic behavior that may harm consumers through Google's control of online advertising markets and search traffic, the report noted. 2. Drugmaker AbbVie (ABBV) said that China is testing an HIV drug as a treatment for symptoms of the new coronavirus that is rapidly spreading, according to Reuters. China health authorities requested the drug to help with the government's efforts to address the crisis, according to Adelle Infante, a spokeswoman for AbbVie. Meanwhile, Starbucks (SBUX) has closed all shops and suspended delivery services in China's Hubei province for the week-long Lunar New Year holiday amid the new coronavirus outbreak, according to Reuters. Starbucks said that the move is out of "health concerns" for its customers and employees, the report noted. 3. Big tech companies, including Amazon (AMZN), Microsoft (MSFT), and Alphabet, are competing for a bigger slice of the esports live-streaming business, which could present an opportunity for investors, Connor Smith wrote in this week's edition of Barron's. Esports events-where the best players compete in games like League of Legends, Activision Blizzard's (ATVI) Overwatch, and Valve's Dota 2 and Counter-Strike: Global Offensive-are attracting young people, much the way traditional sports had for generations, the author noted. 4. Sony's (SNE) "Bad Boys for Life" won this weekend's domestic box office in its second outing, earning $34M to finish Sunday with a total of $120.6M. Worldwide, the movie crossed the $200M mark after grossing another $42M overseas from 58 markets for a foreign cume of $95M and $215.6M globally. "Bad Boys for Life" sports an A CinemaScore and a 76% Rotten Tomatoes rating. 5. HP Inc. (HPQ) saw a positive mention in this week's edition of Barron's, while Omnicom Group (OMC) and Interpublic Group (IPG) in the U.S., Publicis Groupe (PUBGY) in Paris, and WPP (WPP) were mentioned cautiously.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
First Analysis sees continued top-line momentum in 2020 for LiveRamp » 18:48
01/26/20
01/26
18:48
01/26/20
18:48
RAMP

LiveRamp

$42.84 /

-0.06 (-0.14%)

First Analysis analyst…

First Analysis analyst David Gearhart believes LiveRamp should be able to maintain "strong" revenue growth into the foreseeable future combined with rising margins as it benefits from the trend of verticals broadly moving to leverage disparate data to improve customer outcomes. The analyst reiterates a Strong Buy rating and $63 price target on the shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Box Office Battle: 'Bad Boys for Life' stays number 1 with another $34M » 18:07
01/26/20
01/26
18:07
01/26/20
18:07
T

AT&T

$38.49 /

-0.14 (-0.36%)

, CMCSA

Comcast

$44.60 /

-1.05 (-2.30%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

, SNE

Sony

$71.89 /

-0.7 (-0.96%)

, LGF.A

Lionsgate

$10.31 /

-0.22 (-2.09%)

, LGF.B

Lionsgate

$9.62 /

-0.245 (-2.48%)

, DIS

Disney

$140.10 /

-2.12 (-1.49%)

, VIACA

ViacomCBS

$39.11 /

-1.71 (-4.19%)

, VIAC

ViacomCBS

$35.78 /

-1.21 (-3.27%)

"Box Office Battle" is…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
TowneBank reported strongest quarter of year, says Keefe Bruyette » 17:56
01/26/20
01/26
17:56
01/26/20
17:56
TOWN

TowneBank

$27.59 /

-0.27 (-0.97%)

Keefe Bruyette analyst…

Keefe Bruyette analyst Catherine Mealor says TowneBank posted its strongest quarter of the year in Q4 with a 5c expense beat with improved growth. The analyst, however, keeps a Market Perform rating on the shares with a $27 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Plug Power to hold a business news update conference call » 17:52
01/26/20
01/26
17:52
01/26/20
17:52
PLUG

Plug Power

$3.89 /

-0.035 (-0.89%)

CEO Marsh discusses…

CEO Marsh discusses preliminary results for the FY19, as well as expansion and growth plans for 2020, on a business news update conference call to be held on January 30 at 10 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Encana to host conference call » 17:50
01/26/20
01/26
17:50
01/26/20
17:50
ECA

Encana

$3.79 /

-0.26 (-6.42%)

Conference call to…

Conference call to provide a detailed review of key operational accomplishments over the last year in the Anadarko Basin will be held on January 29 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Lazard upgraded to Outperform from Market Perform at Keefe Bruyette » 17:35
01/26/20
01/26
17:35
01/26/20
17:35
LAZ

Lazard

$41.98 /

-0.41 (-0.97%)

, HLI

Houlihan Lokey

$51.91 /

-0.48 (-0.92%)

, MC

Moelis

$35.26 /

+0.075 (+0.21%)

Keefe Bruyette analyst…

Keefe Bruyette analyst Michael Brown upgraded Lazard (LAZ) to Outperform from Market Perform with a price target of $48, up from $40. The stock closed Friday down 47c to $41.92. The company has shown the strongest deal flow in recent months and is best positioned to benefit from the recent increase in European deal activity, Brown tells investors in a research note. Further, following recent inflows and a shift in investor sentiment toward emerging markets strategies, Lazard's asset management business could shift from a headwind to a tailwind, the analyst adds. He expects this momentum to lift the company's earnings and shares higher. Brown tonight also downgraded Houlihan Lokey (HLI) to Market Perform and upgraded Moelis (MC) to Outperform.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Moelis upgraded to Outperform from Market Perform at Keefe Bruyette » 17:30
01/26/20
01/26
17:30
01/26/20
17:30
MC

Moelis

$35.26 /

+0.075 (+0.21%)

Keefe Bruyette analyst…

Keefe Bruyette analyst Michael Brown upgraded Moelis to Outperform from Market Perform with a price target of $39, up from $34. The analyst believes 2019 will represent the "trough" in terms of managing director productivity at Moelis. As the company shows a renewed focus on execution, its productivity should inflect and move back toward 2018 levels in 2020 and 2021, Brown tells investors in a research note. He believes returning to a normalized managing director productivity level and hiring pace should support revenue growth into 2021 above consensus expectations.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Houlihan Lokey downgraded to Market Perform from Outperform at Keefe Bruyette » 17:27
01/26/20
01/26
17:27
01/26/20
17:27
HLI

Houlihan Lokey

$51.91 /

-0.48 (-0.92%)

Keefe Bruyette analyst…

Keefe Bruyette analyst Michael Brown downgraded Houlihan Lokey to Market Perform from Outperform with a price target of $53, up from $52. The analyst cites valuation for the downgrade. However, his positive view on the company's business mix remains intact and he continues to believe Houlihan should remain a core holding for investors.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Five cases of coronavirus confirmed in the U.S. after China travel, Reuters says » 17:01
01/26/20
01/26
17:01
01/26/20
17:01
SPY

SPDR S&P 500 ETF Trust

$328.73 /

-2.99 (-0.90%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

Five people in the United…

Five people in the United States, all of whom recently traveled from Wuhan, China, have been diagnosed with the new coronavirus, Reuters' David Henry reports, citing officials of the federal Centers for Disease Control and Prevention. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Starbucks shuts shops, suspends delivery in China's Hubei, Reuters says » 16:56
01/26/20
01/26
16:56
01/26/20
16:56
SBUX

Starbucks

$92.03 /

-1.72 (-1.83%)

Starbucks has closed all…

Starbucks has closed all shops and suspended delivery services in China's Hubei province for the week-long Lunar New Year holiday amid the new coronavirus outbreak, according to Reuters. Starbucks said that the move is out of "health concerns" for its customers and employees, the report notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Fiat Chrysler facing tough road before PSA merger, WSJ reports » 16:49
01/26/20
01/26
16:49
01/26/20
16:49
FCAU

Fiat Chrysler

$13.37 /

-0.05 (-0.37%)

Fiat Chrysler is banking…

Fiat Chrysler is banking on a planned $50B merger with Peugeot maker PSA Group to help it catch up with rival car companies, but in the year or so until the deal gets done, the carmaker risks falling farther behind, The Wall Street Journal's Eric Sylvers reports. The manufacturer of Chrysler cars and Ram trucks faces falling sales volumes around the world, including a small decline in North America, where it generates more than 90% of profit, the author notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Tesla's Musk seeking to allay water concerns at factory site, Reuters reports » 16:43
01/26/20
01/26
16:43
01/26/20
16:43
TSLA

Tesla

$564.89 /

-7.085 (-1.24%)

Tesla's CEO Elon…

Tesla's CEO Elon Musk sought to allay environmental concerns about the electric carmaker's planned factory in Germany, saying the plant would use less water than was estimated originally, according to Reuters. The U.S. company had said in planning documents that the factory would need 372 cubic meters of water from the public drinking water network per hour, sparking protests by local residents earlier this month, the report notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Alibaba's Taobao takes down overpriced face masks, Reuters reports » 16:40
01/26/20
01/26
16:40
01/26/20
16:40
BABA

Alibaba

$213.65 /

-5.49 (-2.51%)

Alibaba's Taobao…

Alibaba's Taobao marketplace said that it has removed sales of face masks from shops that show "unstable prices or false advertising," as prices for the products surged as Chinese consumers race to protect themselves from the coronavirus outbreak, according to Reuters. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
WeWork signs deal with SoftBank-backed Gympass, Reuters says » 16:36
01/26/20
01/26
16:36
01/26/20
16:36
WE

We Company

$0.00 /

+ (+0.00%)

, SFTBY

SoftBank

$0.00 /

+ (+0.00%)

, SFTBF

SoftBank

$0.00 /

+ (+0.00%)

WeWork (WE) has signed a…

WeWork (WE) has signed a deal to provide space to 250 employees of gym membership app company Compass in New York, the latest example of the U.S. office-sharing start-up's majority owner, SoftBank (SFTBY), using its connections to buoy its business, Reuters' Joshua Franklin writes, citing people familiar with the matter. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
AbbVie says China testing HIV drug to treat new coronavirus, Reuters reports » 16:31
01/26/20
01/26
16:31
01/26/20
16:31
ABBV

AbbVie

$83.53 /

-1.73 (-2.03%)

Drugmaker AbbVie said…

Drugmaker AbbVie said that China is testing an HIV drug as a treatment for symptoms of the new coronavirus that is rapidly spreading, according to Reuters. China health authorities requested the drug to help with the government's efforts to address the crisis, according to Adelle Infante, a spokeswoman for AbbVie. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
State AGs, DOJ officials to meet, coordinate on Google probe, Reuters says » 16:27
01/26/20
01/26
16:27
01/26/20
16:27
GOOGL

Alphabet Class A

$1,465.80 /

-19.06 (-1.28%)

, GOOG

Alphabet

$1,466.47 /

-19.67 (-1.32%)

U.S. state attorneys…

U.S. state attorneys general will meet Justice Department attorneys next week to share information on their investigations into Alphabet's Google, Reuters' Nandita Bose write, citing two sources familiar with the matter. The probes revolve around monopolistic behavior that may harm consumers through Google's control of online advertising markets and search traffic, the report notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
NantHealth GPS Cancer platform data reveals opportunities in colorectal cancer » 16:17
01/26/20
01/26
16:17
01/26/20
16:17
NH

NantHealth

$1.35 /

-0.05 (-3.57%)

NantHealth has announced…

NantHealth has announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer patients during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology. NantHealth's presentation utilized data on whole exome DNA tumor and paired germline and matched deep whole transcriptomic sequencing to identify a higher percentage of CRC patients with HER2 signaling than conventional methods of immunohistochemistry or fluorescence in-situ hybridization. ERBB2 gene expression was evaluated using NantOmics Nant50 gene classifier, which separates patients into subgroups that have been well established in breast cancer. The application of this tool to colorectal cancer proved surprising with greater than expected HER2 positive patients with a normally expected distribution of CMS classification. This finding suggests a possible utility for this tool in a new clinical setting. In addition, the HER2 enriched group did not show differentially expressed mutations in other targetable genes such as PIK3CA and BRAF, highlighting the potential importance of HER2 targeting in this population.

Hot Stocks
NantHealth announces real-world data on treatment patterns for patients with CRC » 16:11
01/26/20
01/26
16:11
01/26/20
16:11
NH

NantHealth

$1.35 /

-0.05 (-3.57%)

NantHealth has announced…

NantHealth has announced new real-world data on treatment patterns for patients with advanced colorectal cancer during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology. NantHealth's presentation examined therapeutic preferences and treatment patterns among advanced CRC patients using data from NantHealth's Eviti Connect, an evidence-based treatment intelligence and web-based oncology decision support platform. Detailed information from 6,325 treatment plans was analyzed to identify treatment patterns using regorafenib and trifluridine + tipiracil for advanced CRC patients as third-line of therapy. National Comprehensive Cancer Network guidelines state that regorafenib and trifluridine+tipiracil are both treatment options for patients who have progressed through all available regimens. Across all 6,325 treatment plans submitted for this patient population, regorafenib or trifluridine+tipiracil was the submitted treatment in 361 of the treatment plans, making them the 9th and 13th most frequently requested drugs in this setting. While the total number of treatment plans for regorafenib was higher than that for trifluridine+tipiracil, the submission of trifluridine+tipiracil has increased over time, consistent with the latter drug's more recent introduction into the market.

Hot Stocks
New Boeing 777X completes first flight » 16:06
01/26/20
01/26
16:06
01/26/20
16:06
BA

Boeing

$323.04 /

+5.25 (+1.65%)

, GE

General Electric

$11.71 /

-0.07 (-0.59%)

The new Boeing (BA) 777X…

The new Boeing (BA) 777X jetliner took to the skies on Saturday, entering the next phase of its test program. Based on the 777 and with proven technologies from the 787 Dreamliner, the 777X took off in front of thousands at Paine Field in Everett, Washington, at 10:09 a.m. local time for a three-hour, 51-minute flight over Washington state before landing at Seattle's Boeing Field. The first of four dedicated 777-9 flight test airplanes, WH001 will now undergo checks before resuming testing in the coming days. The test fleet, which began ground testing in Everett last year, will endure a comprehensive series of tests and conditions on the ground and in the air over the coming months to demonstrate the safety and reliability of the design. The newest member of Boeing's market-leading widebody family, the 777X will deliver 10% lower fuel use and emissions and 10% lower operating costs than the competition through advanced aerodynamics, the latest generation carbon-fiber composite wing and the most advanced commercial engine ever built, GE (GE) Aviation's GE9X. Boeing expects to deliver the first 777X in 2021. The program has won 340 orders and commitments from carriers around the world, including ANA, British Airways, Cathay Pacific Airways, Emirates, Etihad Airways, Lufthansa, Qatar Airways and Singapore Airlines.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Naitonal Marine Manufacturers Association to hold ashow » 04:55
01/26/20
01/26
04:55
01/26/20
04:55

New York Boat Show will…

New York Boat Show will be held in New York on January 22-26.

Periodicals
HP stock 'a good bet,' Barron's says » 14:56
01/25/20
01/25
14:56
01/25/20
14:56
XRX

Xerox

$35.52 /

-0.71 (-1.96%)

, HPQ

HP Inc.

$21.99 /

-0.115 (-0.52%)

For more than two months…

For more than two months now, Xerox (XRX) has been pushing HP Inc. (HPQ) to accept its $32B, $22 a share takeover bid and now it is done asking, with Xerox launching a proxy fight for control of HP and nominating 11 directors to replace the latter's entire board, Eric Savitz writes in this week's edition of Barron's. HP has made it clear that it would prefer to lever up and buy back huge amounts of stock, rather than submit to a Xerox offer that it considers inadequate, but a higher bid could soften HP's position, the author notes. In either scenario, HP investors are likely to benefit, the report adds. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Investors should run away from ad agencies despite Super Bowl, Barron's says » 14:43
01/25/20
01/25
14:43
01/25/20
14:43
BUD

AB InBev

$77.74 /

-0.47 (-0.60%)

, FB

Facebook

$217.89 /

-1.76 (-0.80%)

, OMC

Omnicom

$77.71 /

-1.05 (-1.33%)

, IPG

Interpublic Group

$23.41 /

-0.13 (-0.55%)

, PUBGY

Publicis

$0.00 /

+ (+0.00%)

, WPP

WPP

$65.07 /

-0.81 (-1.23%)

, GOOG

Alphabet

$1,466.47 /

-19.67 (-1.32%)

, GOOGL

Alphabet Class A

$1,465.80 /

-19.06 (-1.28%)

, ACN

Accenture

$208.56 /

-2.16 (-1.03%)

, IBM

IBM

$140.54 /

-2.36 (-1.65%)

, CRM

Salesforce

$182.11 /

-1.89 (-1.03%)

, ORCL

Oracle

$54.07 /

-0.91 (-1.66%)

Super Bowl commercials…

Super Bowl commercials this year will feature a healthy mix of regulars like Bud Light (BUD), brands returning from long breaks and first timers like Facebook (FB) Jack Hough writes in this week's edition of Barron's. Bu shares of big, pure-play advertising agencies - like Omnicom Group (OMC) and Interpublic Group (IPG) in the U.S., Publicis Groupe (PUBGY) in Paris, and WPP (WPP) in London - may hold less appeal than modest valuations advertise, he contends. The long shift of advertising dollars from traditional venues to platforms such as Facebook and Google (GOOG) has prompted technology companies to get in on the marketing game, and agencies competing with one another for new accounts might also find themselves defending against Accenture (ACN), IBM (IBM), Salesforce.com (CRM), and Oracle (ORCL). Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.